Idelalisib Shows Efficacy in Relapsed CLL and Lymphoma Medscape This trial showed that idelalisib used in combination with rituximab (Rituxan, Genentech/Roche) offered an option for patients with relapsed CLL who were unable to tolerate chemotherapy. The company filed these data with the FDA on December 6, 2013, ... |
